Recognizing and Responding to Inadequately Treated Major Depressive Disorder (MDD): A Nursing Perspective

Mary D Moller, DNP, ARNP, PMHCNS-BC, CPRP, FAAN
Associate Professor, Pacific Lutheran University School of Nursing, Tacoma WA

Georgia Stevens, PhD, APRN, PMHCNS-BC
Director, P.A.L. Associates
Partners in Aging & Long-term Caregiving
Washington, DC

© Otsuka America Pharmaceutical, Inc., Rockville, MD

September 2015      MRC2.CORP.D.00052
This program is paid for by Otsuka America Pharmaceutical, Inc. and Lundbeck, LLC. The speaker is a paid contractor of Otsuka America Pharmaceutical, Inc.
PsychU Virtual Forum Rules of Engagement:

Otsuka America Pharmaceutical, Inc. (OAPI) and Lundbeck, L.L.C. have entered into collaboration with Open Minds, L.L.C. to explore new ways of bringing/increasing awareness around serious mental illness.

OAPI/Lundbeck’s interaction with Open Minds is through PsychU, an online, non-branded portal dedicated to providing information and resources on important disease state and care delivery topics related to mental illness. One of the methods employed for the sharing of information will be the hosting of virtual fora. Virtual fora conducted by OAPI/Lundbeck are based on the following parameters:

When conducting medical dialogue, whether by presentation or debate, OAPI/Lundbeck and/or its paid consultants aim to provide the viewer with information that is accurate, not misleading, scientifically rigorous, and does not promote OAPI/Lundbeck products.

OAPI/Lundbeck and/or their paid consultants do not expect to be able to answer every question or comment during a PsychU Virtual Forum; however, they will do their best to address important topics and themes that arise.

OAPI/Lundbeck and/or their paid consultants are not able to provide clinical advice or answer questions relating to specific patient’s condition.

Otsuka and Lundbeck employees and contractors should not participate in this program (e.g., submit questions or comments) unless they have received express approval to do so from Otsuka Legal Affairs.

OAPI and Lundbeck operate in a highly regulated and scrutinized industry. Therefore, we may not be able to discuss every issue or topic that you are interested in, but we will do our best to communicate openly and directly. The lack of response to certain questions or comments should not be taken as an agreement with the view posed or an admission of any kind.
Objectives

- Discuss the burden of MDD on the individual and society
- Explore the negative impact of residual symptoms
- Identify patient and treatment characteristics associated with a poor treatment response
- Discuss evidence for the treatment of patients with MDD and practical guidelines

MDD, major depressive disorder.
BURDEN OF MDD

Mary D Moller, DNP, ARNP, PMHCNS-BC, CPRP, FAAN
Introduction

• Depression is the most common diagnosis among patients seen by psychiatrists in the US\(^1\)

• MDD is a serious, chronic, disabling illness affecting more than 350 million people worldwide\(^2\)

• MDD results in a substantial burden of disease to both the individual and society\(^3\)

• Residual symptoms are common and cause significant psychosocial and occupational functional impairment\(^4,5\)

MDD, major depressive disorder; US, United States.

The information provided by PsychU is intended for your educational benefit only. It is not intended as, nor is it a substitute for medical care or advice or professional diagnosis. Users seeking medical advice should consult with their physician or other healthcare professional.

Lifetime Prevalence of MDD

- Overall lifetime prevalence of MDD across all ages is 16.6%

MDD, major depressive disorder.

Link Between Depression and Other Illnesses

When these rates were compared with subjects without reported mental illness in the past year, the differences in all chronic health conditions were statistically significantly different at the 0.05 level.

Burden of Disease to the Individual

• Physical:
  – MDD is a consistent predictor of the subsequent first onset of a variety of chronic physical disorders, including arthritis, asthma, cardiovascular disease, diabetes, chronic pain, and certain types of cancer

• Financial:
  – Incomes of people with MDD are substantially lower than those without depression

• Education:
  – MDD is associated with a 60% elevated risk of failure to complete secondary school than otherwise comparable youth

MDD, major depressive disorder.
Suicide Risk

• Patients with MDD are roughly 20 times more likely to commit suicide than the general population

• Attempts at suicide among patients with MDD are highly associated with the occurrence and overall severity of MDD symptoms

• Increased time spent depressed is predictive of suicide attempts in this population

MDD, major depressive disorder.
DISCUSSION
DISCUSSION
RESIDUAL SYMPTOMS IN MDD

Georgia Stevens, PhD, APRN, PMHCNS-BC
Remission Is the Goal

- **Remission**
  - MADRS: total score ≤ 8\(^1\)
  - HAM-D: 25% to 50%\(^2\)

- **Response**
  - MADRS: ≥ 50%\(^1\)
  - HAM-D: < 25%\(^2\)

- **Partial Response**

- **Nonresponse**

Remission is also defined as attainment of a virtually asymptomatic status (17-item HAM-D score ≤ 7) for at least 2 consecutive weeks.\(^3\)

---

\(^1\) Weisler R et al. CNS Spectrums. 2009;14(6):299-313;
\(^3\) Frank E et al. Arch Gen Psychiatry. 1991;48:851-855 et al.

The information provided by PsychU is intended for your educational benefit only. It is not intended as, nor is it a substitute for medical care or advice or professional diagnosis. Users seeking medical advice should consult with their physician or other healthcare professional.
Common Unresolved or Residual MDD Symptoms

Estimated frequencies:\(^1\):

- Sleep disturbances (44%)
- Fatigue (38%)
- Diminished interest or pleasure (27%)
- Guilt (≈ 25%)
- Concentration difficulties (≈ 25%)
- Disturbances in mood (≈ 15%)
- Weight issues (≈ 15%)
- Disturbances in psychomotor activity (≈ 5%)
- Suicidal ideation (≈ 5%)

Other residual/unresolved MDD symptoms include: core mood symptoms,\(^2\) anxiety,\(^2,3\) irritability and/or inner tension,\(^3\) somatic symptoms (including pain),\(^2,4\) sexual dysfunction,\(^3\) and impairment of work and/or activities\(^2\)

MDD, major depressive disorder.
Impact of Residual Symptoms on Patient Functioning and Outcomes

- Residual symptoms cause significant and often persistent psychosocial and occupational functional impairment\(^1,2,3\)
- Patients being treated for MDD who have residual symptoms have an increased risk of depressive relapse\(^4,5\)

<table>
<thead>
<tr>
<th>Author</th>
<th>N</th>
<th>Time Followed</th>
<th>Relapsed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paykel(^4)</td>
<td>70</td>
<td>15 months</td>
<td>76% of patients with residual symptoms&lt;br&gt;25% of patients with no residual symptoms</td>
</tr>
<tr>
<td>Pintor(^5)</td>
<td>139</td>
<td>4 years</td>
<td>91% of patients with partial remission&lt;br&gt;51% of patients with complete remission</td>
</tr>
</tbody>
</table>

- Patients with residual symptoms tend to have poor psychosocial functioning\(^6\)

MDD, major depressive disorder.

Remission as Goal of Treatment

• Only approximately 28% of patients treated for MDD achieve remission* following treatment with a single antidepressant¹

• Partial response (indicated by a 25% to 49% reduction in depressive symptoms) is common²

• Patients not achieving a full remission typically suffer from troubling residual symptoms²

• Even patients considered to be fully remitted report experiencing at least one residual symptom³,⁴

• Ideally, the goal of treatment for MDD is for patients to achieve full remission⁵

*Remission defined as a score of ≤5 on the Hamilton Depression Rating Scale.
MDD, major depressive disorder.

2. Fava M. J Psychopharm. 2006;20(3):29-34;
Significant Challenges Exist Surrounding the Treatment of MDD

- There is significant unmet need in the treatment of MDD:
  - under-treatment due to misdiagnosis or underdiagnosis\(^1\)
  - low rates of adherence and persistence to therapy,\(^2\) potentially influenced by:
    - slow onset of action: antidepressants require 4–6 weeks to achieve full therapeutic effect\(^3\)
    - lack of efficacy: a significant proportion of patients fail to remit or only partially remit despite adequate therapy\(^4,5\)
    - poor tolerability: adverse events associated with pharmacologic agents may reduce adherence and persistence\(^3\)
  - low rates of guideline-concordant follow up\(^6\)

MDD, major depressive disorder.

Adherence to Therapy Is a Key Issue in Treating Patients With MDD

• The association between prescriber specialty, follow-up visits, and proportion of patients to complete antidepressant regimen was estimated retrospectively using data from a large national health plan (N = 4102)¹:
  – overall, less than half of patients completed the acute phase of therapy and approximately only 1/5 completed both the acute and continuation phase¹

• These results suggest improved adherence to antidepressants is seen when proper provider support is in place and patients participate in frequent follow-up

47%
Completed acute phase of therapy

21%
Completed both acute and continuation phase of therapy

MDD, major depressive disorder.

Urgency to Treat Residual Symptoms

- Residual depressive symptoms are associated with an increased risk of relapse and poor psychosocial functioning\(^1,2\)

- Adequate pharmacological intervention early in the disease is important to reduce the amount of the time in a depressed state, thereby decreasing the risk of suicide\(^1,2\)

DISCUSSION
RESPONSE TO ANTIDEPRESSANT TREATMENT IN MDD

Mary D Moller, DNP, ARNP, PMHCNS-BC, CPRP, FAAN
Predicting Patient Response to Antidepressant Treatment


Baseline Predictors

- Socio-demographic Qualities
- Illness Characteristics
- Symptom Presentation
- Comorbid Conditions

Process Predictors

- Change in Symptom Severity
- Treatment-related Side Effects
- Patient Adherence
Early Improvement Is Common and Predicts Remission

- Earlier onset of response before 2 weeks is common and highly predictive of later outcome\(^1\)-\(^3\)
- If no improvement is observed after 2 weeks, treatment should be adjusted or changed immediately\(^4\)

Identifying the Inadequately Treated Patient

- Measurement tools for assessing severity of depression used during the first 2–4 weeks of antidepressant treatment can accurately predict the likelihood of a response or lack of response to treatment after a longer term (8 weeks)¹
- Assessment tools to evaluate changes in symptom states during the first 4 weeks of treatment can also predict treatment response at 12 weeks²
  - Dividing the HAM-D-17 into symptom clusters (mood, sleep/psychic anxiety, appetite, and somatic anxiety/weight) and evaluating change scores at 4 weeks correctly assigned up to 70% of patients as late responders or nonresponders at 12 weeks

HAM-D-17, 17-item Hamilton Depression Rating Scale.

EVIDENCE FOR THE TREATMENT OF PATIENTS WITH MDD AND PRACTICAL GUIDELINES

Georgia Stevens, PhD, APRN, PMHCNS-BC
STAR*D Treatment Algorithm: Examining Different Treatment Strategies in a “Real-world” Setting

**Level 1**
Initial treatment: SSRI

**Level 2**
**Switch to:** SSRI, DNRI, SNRI, or cognitive therapy
Augment with DNRI, 5-HT₁A partial agonist, or cognitive therapy

**Level 2a**
**Switch to:** DNRI or SNRI*

**Level 3**
**Switch to:** NaSSA or TCA
Augment with a mood stabilizer or thyroid hormone†

**Level 4**
**Switch to:** MAOI or NaSSA combined with SNRI

---

*Only for those who failed cognitive therapy; †Only with DNRI, SSRI, or SNRI.

DNRI, dopamine and norepinephrine reuptake inhibitor; MAOI, monoamine oxidase inhibitor; NaSSA, noradrenergic and specific serotonergic antidepressant; SNRI, serotonin norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; STAR*D, Sequenced Treatment Alternatives to Relieve Depression; TCA, tricyclic antidepressant.

# STAR*D Results

## Symptom Remission<sup>a</sup> (% Patients)

<table>
<thead>
<tr>
<th>Level</th>
<th>SSRI (n = 3671)</th>
<th>DNRI (n = 239)</th>
<th>SNRI (n = 250)</th>
<th>Cognitive Therapy (n = 36)</th>
<th>DNRI + SSRI (n = 279)</th>
<th>5HT-1A Partial Agonist + SSRI (n = 286)</th>
<th>Cognitive Therapy + SSRI (n = 65)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Level 1&lt;sup&gt;1,2&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>28%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Level 2&lt;sup&gt;3-5&lt;/sup&gt;</td>
<td>SSRI (n = 238)</td>
<td>DNRI (n = 239)</td>
<td>SNRI (n = 250)</td>
<td>Cognitive Therapy (n = 36)</td>
<td>DNRI + SSRI (n = 279)</td>
<td>5HT-1A Partial Agonist + SSRI (n = 286)</td>
<td>Cognitive Therapy + SSRI (n = 65)</td>
</tr>
<tr>
<td></td>
<td>18%</td>
<td>21%</td>
<td>25%</td>
<td>25%</td>
<td>30%</td>
<td>30%</td>
<td>23%</td>
</tr>
<tr>
<td>Level 3&lt;sup&gt;6,7&lt;/sup&gt;</td>
<td>NaSSA (n = 114)</td>
<td>TCA (n = 121)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>12%</td>
<td>20%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Level 4&lt;sup&gt;8&lt;/sup&gt;</td>
<td>MAOI (n = 58)</td>
<td>NaSSA + SNRI (n = 51)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>7%</td>
<td>14%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Note: Trial was not designed to directly compare switch or augmentation medication treatments.

<sup>a</sup>Defined by exit score ≤ 7 on the HAM-D-17.

ADT, antidepressant therapy; DNRI, dopamine and norepinephrine reuptake inhibitor; HAM-D-17, 17-item Hamilton Depression Rating Scale; MAOI, monoamine oxidase inhibitor; NaSSA, noradrenergic and specific serotonergic antidepressant; SNRI, serotonin norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; STAR*D, Sequenced Treatment Alternatives to Relieve Depression; TCA, tricyclic antidepressant.

Revised APA Guidelines for the Acute-phase Treatment of MDD

Start of medication trial and/or psychotherapy

Initial weeks

If no/partial response:
Assess adherence and increase medication dosage or intensity of psychotherapy

4–8 weeks

No / partial response

Full response:
Continuation-phase treatment

• Reappraise treatment plan (Level I*)
• With medication:
  • Optimize dose of current treatment (Level II*)
  • Switch antidepressant (non-MAOI: Level I; MAOI: Level II)
  • Augment with a second agent (Level II/III) or psychotherapy (Level I)
  • ECT (Level I)
• With psychotherapy:
  • Change intensity or type of psychotherapy (Level II)
  • Combine psychotherapy with medication (Level II)

*Level I = recommended with substantial clinical confidence; Level II = recommended with moderate clinical confidence; (Level III = may be recommended on the basis of individual circumstances).

APA, American Psychiatric Association; ECT, electroconvulsive therapy; MAOI, monoamine oxidase inhibitor; MDD, major depressive disorder.

## Revised APA Guidelines: Augmentation Recommendations for No/Partial Response to Antidepressant Therapy

<table>
<thead>
<tr>
<th>Augmentation Options*</th>
<th>Level of Clinical Confidence (I-III)‡</th>
</tr>
</thead>
<tbody>
<tr>
<td>Psychotherapy</td>
<td>I</td>
</tr>
<tr>
<td>Second Antidepressant Therapy†</td>
<td></td>
</tr>
<tr>
<td>Atypical Antipsychotic</td>
<td>II</td>
</tr>
<tr>
<td>Thyroid Hormone</td>
<td></td>
</tr>
<tr>
<td>Mood Stabilizer</td>
<td></td>
</tr>
<tr>
<td>Anticonvulsant</td>
<td></td>
</tr>
<tr>
<td>Psychostimulant</td>
<td></td>
</tr>
<tr>
<td>Omega-3 Fatty Acid</td>
<td>III</td>
</tr>
<tr>
<td>Folic Acid</td>
<td></td>
</tr>
<tr>
<td>Anxiolytic or Sedative/Hypnotic</td>
<td></td>
</tr>
</tbody>
</table>

*Classes of medication have been used in this table to replace some of the specific drug names.
†Includes non-MAOI and MAOI antidepressants.
‡Level I = recommended with substantial clinical confidence; Level II = recommended with moderate clinical confidence; (Level III = may be recommended on the basis of individual circumstances).

APA, American Psychiatric Association.
## Nonpharmacologic Therapies for MDD

<table>
<thead>
<tr>
<th>Categories of Care</th>
<th>Care Strategies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Psychotherapy</td>
<td>Cognitive Behavioral Therapy (CBT)&lt;sup&gt;1&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>Interpersonal Therapy&lt;sup&gt;1&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>Group Therapy&lt;sup&gt;1&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>Problem Solving Therapy&lt;sup&gt;1&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>Future Directed Therapy (FDT)&lt;sup&gt;2&lt;/sup&gt;</td>
</tr>
<tr>
<td>Alternative Mind-Body Therapy</td>
<td>Relaxation techniques (breathing exercises, meditation, etc)&lt;sup&gt;3&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>Yoga, tai chi, qigong&lt;sup&gt;3&lt;/sup&gt;</td>
</tr>
<tr>
<td>Family/Caregiver Involvement</td>
<td>Family/caregiver involvement in the patient treatment plan facilitates day to day management of chronic difficulties of depression&lt;sup&gt;4&lt;/sup&gt;</td>
</tr>
<tr>
<td>Web-Based Intervention</td>
<td>Deprexis (an interactive program that integrates multiple therapeutic approaches to depression)&lt;sup&gt;5&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

MDD, major depressive disorder.

Challenges and Integrated Care Strategies for MDD

- Patient is feeling somewhat better following antidepressant treatment initiation but complains of lingering feelings of depressed mood.
- Patient is feeling better with antidepressant therapy but complains of insomnia or aches and pains.
- Patient is in obvious need of social support but is not interested in, or does not have access to, help (such as a support group).
- Patient complains that family members do not understand what they are going through and think family members are just angry and frustrated with them.
- Patient is partially responding to antidepressant but expresses feelings of hopelessness and a general low satisfaction with life.

MDD, major depressive disorder.
Measurement-based Care

• Among practitioners, clinical treatment of depression is often associated with wide variations in dosage and duration of treatment\(^1\)

• Measurement-based care was developed as a systematic approach to evaluate patient progress and eliminate variability in patient treatment among physicians
  – In STAR*D, measurement-based care included the routine measurement of symptoms and side effects at each treatment visit; a treatment manual was used by treating physicians that detailed precisely when and how to modify medication regimens or doses based on results of assessments\(^2\)

• A wide variety of physician-rated and patient-rated scales are currently available to evaluate patient symptoms, functioning ability, treatment progress, and side effects\(^3\)
  – For more information, please see: http://www.outcometracker.org/scales_library.php

---

STAR*D, Sequenced Treatment Alternatives to Relieve Depression.


© PsychU. All rights reserved.

The information provided by PsychU is intended for your educational benefit only. It is not intended as, nor is it a substitute for medical care or advice or professional diagnosis. Users seeking medical advice should consult with their physician or other healthcare professional.
Summary

- MDD is a serious, chronic, disabling illness affecting hundreds of millions of individuals worldwide
- Use of assessment tools and measurement-based care may facilitate patient-physician dialogue
- Residual symptoms are common and cause significant psychosocial and occupational functional impairment
- Over 90% of MDD patients experience residual symptoms during the course of treatment
  - These patients are at increased risk for depressive relapse
- Patients with residual symptoms, relapse, and/or suicidality should receive increased vigilance and a more aggressive treatment approach (including combination therapy, psychotherapy, cognitive behavioral therapy, etc)

MDD, major depressive disorder.
QUESTIONS
QUESTIONS